Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

Abstract: An oil fence including an oil filtration membrane includes: a floating member floating on a surface of water; and an oil filtration membrane connected to the floating member, allowing the water to pass therethrough, and rapidly collecting materials such as oil or a hazardous and noxious substance included in the water.

Abstract: The present application relates to a method for selecting an injection-molded article and a method for manufacturing an injection-molded article.

Abstract: An insulin conjugate having improved in vivo duration and stability is provided. The conjugate is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment.

Abstract: Provided is a conjugate in which an immunoglobulin Fc region is linked to an iduronate-2-sulfatase enzyme through a non-peptide polymer linker moiety. Further, provided are a conjugate, a method for preparing the same, and a composition including the same in which a non-peptide polymer linker moiety is specifically linked to an immunoglobulin Fc.

Abstract: A sound absorption structure and a method of manufacturing the same are provided. The sound absorption structure includes a first sound absorption layer comprising first elements of which longitudinal directions are misaligned in a thickness direction of the sound absorption structure, the first sound absorption layer having a first internal filling density and absorbing sound waves of a first reactance frequency; and a second sound absorption layer disposed on the first sound absorption layer, having a second internal filling density different from the first internal filling density, and absorbing sound waves of a second reactance frequency2 different from the first reactance frequency.

Abstract: A method for preparing a conjugate by linking a physiologically active polypeptide, a non-peptidyl polymer linker, and an immunoglobulin constant region via a covalent bond are disclosed. The method enables an efficient preparation of a physiologically active polypeptide conjugate, in which a salt is used in a coupling reaction to improve the problem of low production yield during preparation of the physiologically active polypeptide conjugate.

Abstract: An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.

Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

Abstract: Disclosed is a hydrophilic material oil fence having a double-porous mesh. The hydrophilic material oil fence having the double-porous mesh includes a floating body floating on a water surface, and a skirt coupled to an upper portion and a lower portion of the floating body and made of a hydrophilic material through which a hydrophilic fluid selectively passes. A mesh hole size of a partial region of the skirt and a mesh hole size of the other region of the skirt are different.

Abstract: The present invention relates to an insulin analog conjugate and use thereof.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.

Abstract: The present invention relates to an extrusion die and a method for extruding a sheet using the same, and according to one aspect of the present invention, there is provided an extrusion die comprising a storage part configured to hold a raw material, the storage part defining a first width, a pressure part configured to move the raw material through the storage part, a first die defining a second width less than the first width, such that a flow width of the raw material becomes narrower, a second die in fluid communication with the first die, the second die defining a width that increases from the second width to a third width, such that the flow width of the raw material passing through the first die becomes wider and a flow thickness becomes smaller, and a heating part configured to heat the raw material passing through the second die.

Abstract: The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

Abstract: The present invention provides microstructures using crosslinked hyaluronic acid hydrogels and the method for preparing the same. The present invention for preparing microstructures using crosslinked hyaluronic acid hydrogels allows the preparation of microstructures with a uniform shape and minimum deformation. Furthermore, the microstructures made using crosslinked hyaluronic acid hydrogels in the present invention can improve skin aging, e.g. wrinkles, replenish moisture, easily absorb body fluids due to its outstanding swelling performance, provide a longer duration in the body due to its resistance against a hyaluronic acid hydrolyzing enzyme, enabling the safe delivery of effective components in the body.

Abstract: Provided is a long-acting pharmaceutical composition containing a conjugate comprising a physiologically active polypeptide linked to an immunoglobulin Fc fragment, wherein the composition contains a monomeric conjugate comprising one molecule of the physiologically active polypeptide linked to a single immunoglobulin Fc fragment, and optionally contains a multimeric conjugate comprising two or more molecules of the same physiologically active polypeptide linked to a single immunoglobulin Fc fragment, provided that the molar ratio of the monomeric conjugate to the multimeric conjugate in the composition is at least 19; a physiologically active polypeptide monomer-immunoglobulin Fc fragment conjugate that comprises a physiologically active polypeptide monomer linked via a non-peptidyl linker to an immunoglobulin Fc fragment, wherein the physiologically active polypeptide is linked via the non-peptidyl linker to the immunoglobulin Fc fragment in a monomeric form.

Abstract: The present invention relates to a hyaluronic acid microstructure having excellent solubility characteristics. More specifically, the present invention relates to a biodegradable microstructure comprising crosslinked hyaluronic acid and having excellent solubility characteristics during skin penetration. When the microstructure of the present invention is penetrated into the skin, the solubility characteristics in the skin are excellent, the dissolution rate in the skin can be easily controlled according to the content ratio of the crosslinked hyaluronic acid, and, while effective ingredients provided on the microstructure can be stably delivered into the skin, the release rate of the provided effective ingredients can be easily controlled, and thus the present invention can be used as a transdermal delivery system for pharmacologically active materials or skin improvement materials.